As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Marinus Pharmaceuticals

  • Friday's Range: $5.10-$5.75
  • 52-Week Range: $4.00-$20.72
  • Friday's Volume: 132,,000
  • Three-Month Average Volume: 80,557

Marinus Pharmaceuticals  (MRNS) , a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. This stock closed up 8.7% to $5.62 in Friday's trading session.

From a technical perspective, Marinus Pharmaceuticals ripped sharply higher on Friday right above its 50-day moving average of $5.01 a share and back above its 20-day moving average of $5.43 a share with strong upside volume flows. This high-volume spike to the upside is now quickly pushing shares of Marinus Pharmaceuticals within range of triggering a major breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to clear some near-term overhead resistance levels at $5.75 to $6.09 a share with high volume.

Traders should now look for long-biased trades in Marinus Pharmaceuticals long as it's trending above its 50-day moving average of $5.01 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 80,557 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6.46 to $6.60, or even $7 to $7.50 a share.

Sphere 3D

  • Friday's Range: $1.18-$1.32
  • 52-Week Range: $0.98-$5.73
  • Friday's Volume: 495,000
  • Three-Month Average Volume: 344,673

Sphere 3D  (ANY)  provides virtualization technologies and data management solutions in the Americas, Europe, the Middle East, Africa and the Asia Pacific. This stock traded up 8.4% to $1.29 in Friday's trading session.

From a technical perspective, Sphere 3D ripped sharply higher on Friday right above some near-term support at $1.16 a share and back above its 20-day moving average of $1.28 a share with strong upside volume flows. This high-volume jump to the upside is now quickly pushing shares of Sphere 3D within range of triggering a big breakout trade above some near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.38 to its 50-day moving average of $1.41 a share and then above more resistance at $1.46 a share with high volume.

Traders should now look for long-biased trades in Sphere 3D s as long as it's trending above some near-term support at $1.16 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 344,673 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.55 to around $1.80, or even $2 a share.

Northwest Biotherapeutics

  • Friday's Range: $1.59-$1.68
  • 52-Week Range: $1.28-$12.55
  • Friday's Volume: 583,000
  • Three-Month Average Volume: 453,243

Northwest Biotherapeutics  (NWBO) , a biotechnology company, discovers and develops immunotherapy products to treat cancer in the U.S. and internationally. This stock traded up 4.7% to $1.67 in Friday's trading session.

From a technical perspective, Northwest Biotherapeutics spiked sharply higher on Friday right above its 20-day moving average of $1.54 a share with strong upside volume flows. This stock has been uptrending over the last month, with shares moving higher off its low of $1.28 a share to its recent high of $1.84 a share. During that uptrend, this stock has been making mostly higher lows and higher highs, which is bullish technical price action. This high-volume rip higher on Friday is now quickly pushing shares of Northwest Biotherapeutics within range of triggering a major breakout trade. That trade will trigger if this stock manages to take out its 50-day moving average of $1.75 a share and then above more key resistance at $1.84 a share with high volume.

Traders should now look for long-biased trades in Northwest Biotherapeutics as long as it's trending above its 20-day moving average of $1.54 a share or above more near-term support at $1.40 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 453,243 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.25 to $2.50, or even $2.60 to $2.71 a share.

Chimerix

  • Friday's Range: $5.41-$6.11
  • 52-Week Range: $4.36-$58.04
  • Friday's Volume: 2.68 million
  • Three-Month Average Volume: 2.29 million

Chimerix (CMRX - Get Report) , a biopharmaceutical company, discovers, develops and commercializes oral antivirals in the areas of unmet medical needs in the U.S. This stock traded up 3.8% to $5.90 in Friday's trading session.

From a technical perspective, Chimerix ripped notably higher on Friday right above its 20-day moving average of $5.28 a share and back above its 50-day moving average of $5.60 a share with above-average volume. This high-volume spike higher managed to push shares of Chimerix into its previous gap-down-day zone from February that started just above $7.50 a share. Market players should now look for a continuation move to the upside in the short-term if this stock manages to clear Friday's intraday high of $6.11 a share with strong volume.

Traders should now look for long-biased trades in Chimerix as long as it's trending above its 20-day moving average of $5.28 a share and then once it sustains a move or close above Friday's intraday high of $6.11 a share with volume that hits near or above 2.29 million shares. If that move gets underway soon, then this stock will set up to re-fill some more of its previous gap-down-day zone from February.

Infinity Pharmaceuticals

  • Friday's Range: $6.00-$6.30
  • 52-Week Range: $4.75-$15.22
  • Friday's Volume: 437,000
  • Three-Month Average Volume: 672,306

Infinity Pharmaceuticals  (INFI - Get Report) , drug discovery and development company, discovers, develops and delivers medicines to patients with difficult-to-treat diseases. This stock traded up 2.2% to $6.25 in Friday's trading session.

From a technical perspective, Infinity Pharmaceuticals trended higher on Friday right off its 50-day moving average of $5.95 a share with lighter-than-average volume. This spike higher is now starting to push shares of Infinity Pharmaceuticals within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $6.32 to $6.45 a share and then above more resistance at $6.61 a share with high volume.

Traders should now look for long-biased trades in Infinity Pharmaceuticals as long as it's trending above its 50-day moving average of $5.95 a share or above its 20-day moving average of $5.74 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 672,306 shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6.97 to $7.07, or even $7.50 to its 200-day moving average of $7.90 a share.

IntelliPharmaCeutics International

  • Friday's Range: $2.10-$2.26
  • 52-Week Range: $1.73-$3.92
  • Friday's Volume: 82,000
  • Three-Month Average Volume: 89,927

IntelliPharmaCeutics International  (IPCI) , a pharmaceutical company, engages in the research, development and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. This stock traded up 3.7% to $2.21 in Friday's trading session.

From a technical perspective, IntelliPharmaCeutics International jumped notably higher on Friday right off its 20-day moving average of $2.11 a share and back above its 50-day moving average of $2.21 a share with decent upside volume flows. This stock has been uptrending over the last few weeks, with shares moving higher off its low of $1.94 a share to its recent high of $2.27 a share. During that uptrend, shares of IntelliPharmaCeutics International have been making mostly higher lows and higher highs, which is bullish technical price action. This trend to the upside on Friday is now quickly pushing this stock within range of triggering a major breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $2.26 to $2.27 a share and then above more resistance at $2.40 to $2.50 a share with high volume.

Traders should now look for long-biased trades in IntelliPharmaCeutics International as long as it's trending above some near-term support levels at $2 or at $.194 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 89,927 shares. If that breakout develops soon, then this stock will set up to re-fill some of its previous gap-down-day zone from February that started just above $2.80 a share.

 

Sears Hometown and Outlet Stores

  • Friday's Range: $6.25-$6.70
  • 52-Week Range: $5.06-$9.92
  • Friday's Volume: 32,000
  • Three-Month Average Volume: 51,376

Sears Hometown and Outlet Stores  (SHOS - Get Report)  engages in the retail sale of home appliances, lawn and garden equipment, tools and hardware in the U.S. This stock traded up 5.2% to $6.67 in Friday's trading session.

From a technical perspective, Sears Hometown and Outlet Stores spiked sharply higher on Friday right off its 50-day moving average of $6.18 a share and into breakout territory above some near-term overhead resistance at $6.42 a share with lighter-than-average volume. This jump to the upside is now quickly pushing shares of Sears Hometown and Outlet Stores within range of triggering a major breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $6.75 to around $7 a share with high volume.

Traders should now look for long-biased trades in Sears Hometown and Outlet Stores as long as it's trending above its 20-day moving average of $6.09 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 51,376 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $7.59 to $7.88, or even $8.24 to $8.77 a share.

Biocept

  • Friday's Range: $1.20-$1.30
  • 52-Week Range: $1.05-$4.11
  • Friday's Volume: 140,000
  • Three-Month Average Volume: 196,847

Biocept  (BIOC - Get Report) , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. This stock traded up 3.2% to $1.28 in Friday's trading session.

From a technical perspective, Biocept spiked notably higher on Friday right above some near-term support at $1.15 a share with lighter-than-average volume. This jump to the upside briefly pushed this stock back above its 20-day moving average of $1.29 a share, before it closed just below that level. Shares of Biocept are now starting to trend within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at its 50-day moving average of $1.36 a share and then above more resistance at $1.40 a share with high volume.

Traders should now look for long-biased trades in Biocept as long as it's trending above some near-term support levels at $1.20 or at $1.15 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 196,847 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.47 to $1.50, or even $1.65 to its 200-day moving average of $1.87 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.